New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
09:04 EDTHALOHalozyme resumes enrollment and dosing of patients for PEGPH20 Phase 2 trial
Halozyme Therapeutics announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
News For HALO From The Last 14 Days
Check below for free stories on HALO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
09:05 EDTHALOHalozyme's pancreatic cancer candidate clinical trial approved by FDA to resume
Halozyme announced that the FDA has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial. The trial is designed to evaluate Halozyme's investigational drug PEGPH20 in combination with modified FOLFIRINOX chemotherapy in patients with metastatic pancreatic adenocarcinoma. The study will resume under a revised protocol.
September 15, 2014
09:16 EDTHALOOn The Fly: Pre-market Movers
Subscribe for More Information
September 12, 2014
20:32 EDTHALOFDA approves Baxter's HYQVIA for treatment of primary immunodeficiency
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use